A new gel could heal chronic wounds seven times faster than current standard of care, data suggests. 

Biotechnology company SolasCure has released data from its Phase II trial of the Aurase Wound Gel (AWG), showing the gel demonstrated 22 times faster debridement and seven times faster healing compared to standard of care.  

The gel, which delivers continuous enzymatic debridement while simultaneously activating wound healing, was used in sloughy venous leg ulcers. 

AWG combines a proprietary hydrogel formulation with the active pharmaceutical ingredient (API) tarumase. Following earlier Phase IIa clinical study, which demonstrated a strong safety profile and pain-free application, further studies proved efficacy and dose response in patients with treatment-resistant venous leg ulcers.  

The results indicate a dual mechanism of action where, in addition to continuously removing necrotic tissue, API tarumase activates PAR2 receptors involved in tissue repair, initiating healing pathways from the first application. AWG maintained an excellent safety profile, caused no additional pain to patients, and was associated with improvements in quality of life across physical, psychological, and daily living measures. 

“These Phase II results represent a highly encouraging advance in the treatment of chronic wounds,” Rob Kirsner, Head of Medical Advisory Board at SolasCure, Chairman and Harvey Blank Professor of Dermatology at the University of Miami.  

“From a clinical perspective, the data demonstrate very effective debridement alongside meaningful activation of the biological processes leading to healing.” 

Chronic wounds remain a significant and growing unmet medical need, affecting millions of patients worldwide and placing a substantial burden on healthcare systems. Current therapies primarily focus on wound bed preparation rather than directly stimulating the biological processes required for healing. 

AWG will now be advanced to the next stage of development.